Renova Cream
NDC Package 0187-5150-40

11-digit billing NDC: 00187515040

Package Information

Renova (tretinoin) cream is (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.)RENOVA (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. This formulation utilizes a cream delivery system. Marketed by Bausch Health Us Llc, this product is identified by NDC 0187-5150 and is authorized under FDA application NDA021108.

Identification & Billing

NDC Package Code
0187-5150-40
Package Description
1 TUBE in 1 CARTON / 40 g in 1 TUBE
Product Code
11-Digit Billing Format
00187515040
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Renova
Non-Proprietary Name
Tretinoin
Substance Name
Tretinoin
Dosage Form
Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Usage Information
(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.)RENOVA (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blind, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams.•RENOVA (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis.•RENOVA (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing.•Patients with visible actinic keratosis and patients with a history of skin cancer were excluded from clinical trials of RENOVA (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA (tretinoin cream) 0.02% in these populations are not known at this time.•Neither the safety nor the effectiveness of RENOVA (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established.•Neither the safety nor the efficacy of using RENOVA (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials (see WARNINGS).

Regulatory & Marketing

Labeler Name
Bausch Health Us Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021108
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-31-2000
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0187-5150). Click a package code to view its specific billing and regulatory data.

1 TUBE in 1 CARTON / 2 g in 1 TUBE
1 TUBE in 1 CARTON / 20 g in 1 TUBE
1 BOTTLE, PUMP in 1 CARTON / 44 g in 1 BOTTLE, PUMP
1 TUBE in 1 CARTON / 60 g in 1 TUBE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0187-5150-40 identifies a specific commercial package of 1 tube in 1 carton / 40 g in 1 tube of Renova, a human prescription drug labeled by Bausch Health Us Llc. This cream is formulated for topical use and contains tretinoin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch Health Us Llc on August 31, 2000. The current certification is valid through December 31, 2027.

How is this Bausch Health Us Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00187515040. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0187-5150-40
11-Digit CMS (5-4-2)
00187-5150-40

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.